We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pilot Study Shows Clinical Benefit with Nivolumab in Pediatric Patients with Hypermutant Cancers.
- Authors
Dawson, Charlie
- Abstract
The article reports that immune checkpoint inhibitor nivolumab (Opdivo) appears to be effective in pediatric patients with hypermutant or ultra-hypermutant cancers, a study reported by American Society of Clinical Oncology 2021 annual meeting. Topics include findings contrast with previous pediatric studies of immune checkpoint inhibitors; and context of replication repair deficiency (RRD) and hypermutation, immune checkpoint inhibition therapy.
- Subjects
AMERICAN Society of Clinical Oncology; CHILD patients; NIVOLUMAB; CANCER patients
- Publication
Oncology Practice Management, 2021, Vol 11, Issue 12, p30
- ISSN
2164-4403
- Publication type
Article